NewsBenzingaDBV Technologies此前报告称，已向FDA提交VIASKIN花生贴片用于4至7岁花生过敏儿童的BLA申请，并请求优先审评 DBV Technologies此前报告称，已向FDA提交VIASKIN花生贴片用于4至7岁花生过敏儿童的BLA申请，并请求优先审评 Benzinga 2026.09.30 07:43 (GMT+0) Open on Benzinga Other news Deutsche Bank Initiates Coverage On FormFactor with Buy Rating, Announces Price Target of $200 SBI, Mesh, Money Forward to Form Japan Digital Asset Joint Venture Full Transcript: Rockwell Automation Q3 2026 Earnings Call Meta avoided billions in federal taxes by classifying its data centers as experimental facilities Coinbase Receives CFTC Approval to Operate a Derivatives Clearing Organization Piper Sandler Maintains Overweight on Microsoft, Raises Price Target to $610
